Epalrestat sustained release tablets In the manage...

In the management of diabetic neuropathy, one of the most debilitating complications of diabetes, innovation in pharmaceutical treatments plays a crucial role. EPSTATE SR 150 is a breakthrough formulation containing Epalrestat sustained release (SR) form, offering patients a potent, targeted, and well-tolerated option for nerve protection and symptom control.

Diabetic peripheral neuropathy (DPN) affects a significant number of individuals with diabetes, often leading to chronic pain, tingling, numbness, and reduced mobility. These symptoms not only impair the quality of life but may also lead to serious complications like foot ulcers and infections. EPSTATE SR 150 addresses this issue at the biochemical level by preventing nerve cell damage caused by high blood glucose levels.

By inhibiting a specific enzyme called aldose reductase, Epalrestat reduces the conversion of glucose to sorbitol—a sugar alcohol that accumulates in nerve tissues during hyperglycemia. This accumulation is a key factor in nerve damage, oxidative stress, and inflammation. EPSTATE SR 150 directly tackles this mechanism, providing long-term benefits to patients suffering from chronic diabetic complications.

Key Features and Ingredients

Key Features of EPSTATE SR 150

• Sustained Release Technology: Ensures a consistent and prolonged therapeutic effect, maintaining effective drug levels throughout the day.

• Once-Daily Dosing: Improves patient compliance and simplifies the treatment regimen.

• Aldose Reductase Inhibition: Targets the polyol pathway, the main driver of glucose-induced nerve damage.

• Neuroprotective Effect: Enhances nerve conduction and reduces symptoms associated with diabetic neuropathy.

• Clinically Tested: Proven efficacy and safety in numerous clinical trials for diabetic nerve damage.

Composition

• Active Ingredient: Epalrestat 150 mg (Sustained Release)

• Tablet Form: Film-coated sustained release tablets, designed for gradual drug release and absorption

How EPSTATE SR 150 Works

Epalrestat, the active pharmaceutical ingredient in EPSTATE SR 150, belongs to a class of drugs known as aldose reductase inhibitors (ARIs). During persistent hyperglycemia (high blood sugar), the body uses alternate pathways to process excess glucose. One such route is the polyol pathway, where aldose reductase converts glucose into sorbitol.

Excessive accumulation of sorbitol in nerve cells causes osmotic and oxidative stress, leading to cellular damage, impaired nerve function, and symptoms like pain, tingling, and numbness. By inhibiting aldose reductase, EPSTATE SR 150 reduces sorbitol buildup, thereby:

• Protecting nerve cells from damage

• Reducing oxidative stress

• Preserving nerve function

• Delaying the progression of diabetic neuropathy

This mechanism offers a disease-modifying effect, rather than just symptom suppression, which sets EPSTATE SR 150 apart from conventional analgesics or anti-inflammatory medications.

Usage Guidelines

Dosage and Administration

• Recommended Dosage: One tablet (150 mg) once daily, preferably after a meal

• Route of Administration: Oral

• Swallow whole with water; do not chew or crush the tablet

Precautions

• Suitable for adults only; not recommended for pediatric use unless prescribed by a specialist

• Use with caution in patients with liver disorders

• Regular monitoring of blood sugar levels is advised

• Continue other antidiabetic medications as prescribed

🔔 Always consult a healthcare provider before starting or stopping any medication.

Who Should Use EPSTATE SR 150?

• Individuals diagnosed with type 1 or type 2 diabetes experiencing early signs of nerve damage

• Patients with long-standing diabetes who are at risk of developing diabetic neuropathy

• Diabetic patients complaining of sensory disturbances such as burning, tingling, or numbness in hands and feet

• People seeking a preventive therapy to protect nerve health in diabetes

Why Choose EPSTATE SR 150?

• Mechanism-based therapy: Not just a painkiller—it targets the actual cause of neuropathy

• Once-daily sustained release formulation ensures all-day symptom control

• Well-tolerated with minimal side effects

• Compatible with most oral antidiabetic medications

• Backed by clinical research and global usage

Conclusion

EPSTATE SR 150 is more than just a tablet—it is a strategic approach to combating the underlying causes of diabetic nerve damage. By delivering Epalrestat in a sustained release format, this innovative therapy provides long-lasting neuroprotection, enhances patient adherence, and contributes to overall diabetes care.Steris Healthcare Pvt Ltd, known as Sterispharma, was founded in February 2018 by a team of experienced professionals in the pharmaceutical industry. Headquartered in Navi Mumbai, the company holds certifications from WHO, GMP, and ISO, reflecting its dedication to maintaining high standards of quality and safety. Sterispharma’s mission is to provide affordable, high-quality medications across India, strictly adhering to WHO guidelines. With the convenience of an online pharmacy, customers can easily order medicines with home delivery options. The company offers a wide range of healthcare products, catering to various medical needs, from rare disease treatments to essential healthcare products. Sterispharma's product range includes solutions for Cardiology, Asthma, Respiratory Issues, Nasal Conditions, Diabetes, Endocrinology, Gastroenterology, Orthopedics, Anti-infectives/Antibiotics, General Medicine, Urology, Neurology, Nephrology, Oncology, Gynecology, Pediatrics, Dental Care, and Dermatology. Medicines can be conveniently ordered via Our websites—Sterisonline, Sterisindia, and Sterispharma.